Condition: Hepatocellular Carcinoma · Hepatocellular Cancer · Sponsor: The Methodist Hospital Research Institute
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
This description comes directly from the study's public registry record.
Darrel Cleere, BSN · 713-441-6232 · dwcleere@houstonmethodist.org
Shondra Word · 713-441-5122 · sword@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist Research Institute | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05185505